161 Oyster Point Blvd, Suite 200
South San Francisco
2 articles with Nura Bio
Structural and Mechanistic Regulation of SARM1’s Transition from Autoinhibited to Neurotoxic State Published in CELL REPORTS
Nura Bio Inc., a biopharma company created to discover and develop life-changing neuroprotective drugs, today announced the publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS.
Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing
Targeting axonal degeneration and neuroinflammation, early hallmarks of several acute and chronic neurological diseases